Laport G F, Williams S F
Section of Hematology/Oncology, University of Chicago Hospital, IL 60637, USA.
Semin Oncol. 1998 Aug;25(4):503-17.
Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term survival. High-dose chemotherapy (HDC) with stem cell rescue has emerged as the treatment of choice for such patients as long-term disease-free survival can be obtained in a significant number of these patients. Dose-intensive treatment has been equivocally shown effective for certain patients with Hodgkin's and NHL, whether or not chemosensitivity is shown before transplant. However, HDC has yet to consistently yield durable responses in patients with indolent NHL. Additionally, perhaps the International Prognostic Index can now help identify "high-risk" NHL patients who may benefit from investigative approaches such as frontline HDC.
如今，许多霍奇金淋巴瘤和非霍奇金淋巴瘤（NHL）患者可通过联合化疗和/或放疗治愈。然而，对于初始治疗反应欠佳的患者或难治性或复发性疾病患者，单纯挽救性治疗通常不足以实现长期生存。大剂量化疗（HDC）联合干细胞救援已成为这类患者的首选治疗方法，因为相当一部分此类患者可获得长期无病生存。剂量密集型治疗对某些霍奇金淋巴瘤和NHL患者的有效性尚不明确，无论移植前是否显示化疗敏感性。然而，HDC尚未在惰性NHL患者中持续产生持久反应。此外，国际预后指数或许现在有助于识别可能从一线HDC等研究性方法中获益的“高危”NHL患者。
